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Background: The outcome of patients suffering from pulmonary arterial hypertension (PAH) are predominantly
determined by the response of the right ventricle to the increase afterload secondary to high vascular
pulmonary resistance. However, little is known about the effects of the current available or experimental
PAH treatments on the heart. Recently, inflammation has been implicated in the pathophysiology of PAH.
N-acetylcysteine (NAC), a well-known safe anti-oxidant drug, has immuno-modulatory and cardioprotective
properties. We therefore hypothesized that NAC could reduce the severity of pulmonary hypertension (PH) in
rats exposed to monocrotaline (MCT), lowering inflammation and preserving pulmonary vascular system and
right heart function.
Methods: Saline-treated control, MCT-exposed, MCT-exposed and NAC treated rats (day 14–28) were evaluated at
day 28 following MCT for hemodynamic parameters (right ventricular systolic pressure, mean pulmonary arterial
pressure and cardiac output), right ventricular hypertrophy, pulmonary vascular morphometry, lung inflammatory
cells immunohistochemistry (monocyte/macrophages and dendritic cells), IL-6 expression, cardiomyocyte hypertrophy
and cardiac fibrosis.
Results: The treatment with NAC significantly decreased pulmonary vascular remodeling, lung inflammation,
and improved total pulmonary resistance (from 0.71 ± 0.05 for MCT group to 0.50 ± 0.06 for MCT + NAC group,
p < 0.05). Right ventricular function was also improved with NAC treatment associated with a significant decrease in
cardiomyocyte hypertrophy (625 ± 69 vs. 439 ± 21 μm2 for MCT and MCT + NAC group respectively, p < 0.001) and
heart fibrosis (14.1 ± 0.8 vs. 8.8 ± 0.1% for MCT and MCT + NAC group respectively, p < 0.001).
Conclusions: Through its immuno-modulatory and cardioprotective properties, NAC has beneficial effect on
pulmonary vascular and right heart function in experimental PH.
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Pulmonary arterial hypertension (PAH) is a rare condition
characterised by small pulmonary artery remodeling, lead-
ing to chronic pre-capillary pulmonary hypertension (PH)
(mean pulmonary artery pressure above 25 mmHg and
mean pulmonary artery wedge pressure below 15 mmHg),
elevated pulmonary vascular resistance and right heart
failure [1]. Unfortunately, despite medical treatments,
progression of disease leads to right heart dysfunction,
low cardiac output (CO), progressive decline in exercise
capacity and eventually the development of end-organ
insufficiency [1]. In addition to vasoconstriction, remod-
eling and thrombosis, inflammatory mechanisms play a
key role in both human and experimental PH [2-8].
Pro-inflammatory cytokines including interleukin (IL)-1β
and IL-6 have been reported to be elevated in both human
idiopathic PAH (IPAH) [9] and monocrotaline (MCT)-
induced PH [10,11]. Moreover in IPAH, infiltrates of
macrophages and lymphocytes were found in the range
of plexiform lesions with local expression of pro-
inflammatory chemokines [12-14]. Dendritic cells were
also reported in vascular pulmonary lesions and sus-
pected to be involved in pulmonary vascular remodeling
[15]. Pulmonary vascular remodeling promotes eleva-
tion of pulmonary vascular resistance leading to right
ventricular hypertrophy characterized by cardiomyocyte
hypertrophy and extracellular matrix changes with fibrosis.
Maladaptative neurohormonal signaling, oxidative stress
and inflammation in the heart have been suggested
as processes possibly accelerating the development of
the right-heart failure in PAH [16]. Recently, oxidative
stress was speculated to play a role in the pathophysi-
ology of human and experimental PH [17-20]. Markers
of oxidative stress were found in pulmonary vascular
lesions of PAH patients [21] and urinary isoprostanes
have recently been shown to independently correlate with
survival [22]. Inflammation and oxidative stress are thus
two interlinked pathophysiological processes promoting
a vicious circle in PAH pathophysiology [23].
N-acetylcysteine (NAC) is an amino acid derived from
cysteine with anti-inflammatory and antioxidant prop-
erties already used in the clinical setting, for example
in acetaminophen intoxication, idiopathic pulmonary
fibrosis, bronchitis, ischemia-reperfusion injury, cardiac
injury and doxorubicin cardiotoxicity [24]. It is both an
analogue and a precursor of intracellular glutathione
synthesis leading to restoration of the cell redox status.
NAC is also known to inhibit pro-inflammatory cytokine
TNF-α and IL-1β production and NF-κB activation, to
decrease the number of inflammatory cells in the lung
of rats in lung injury models and to impair chemotaxis
of polymorphonuclear leukocytes and monocytes [25,26].
Finally, NAC has been reported to provide cardiac pro-
tection in animal models through its antioxidant andanti-inflammatory properties [27,28]. Acting on oxi-
dative stress and inflammation, NAC has therefore
immuno-modulatory properties associated with cardio-
protective effects, which could be beneficial in the man-
agement of PAH.
In this study, we hypothesized that NAC could reduce
the severity of MCT-induced PH through an immuno-
modulatory and cardioprotective process preserving
pulmonary vascular system and right heart function.
Material and methods
Study design
Experiments were conducted according to the European
Union regulations (Directive 86/609 EEC) for animal
experiments and complied with our institution's guide-
lines for animal care and handling. The animal facility is
licensed by the French Ministry of Agriculture (agree-
ment N° B92-019-01). This study was approved by the
Committee on the Ethics of Animal Experiments CEEA26
CAPSud. All animal experiments were supervised by
Dr. Frederic Perros (agreement delivered by the French
Ministry of Agriculture for animal experiment N° A92–392).
All efforts were made to minimize animal suffering.
Male Sprage-Dawley rats (220–250 g) were maintained
in a temperature-controlled room with a 12:12 light–
dark cycle and randomly divided into 1) Saline-treated
control group (n = 15); 2) MCT-exposed group (n = 15)
and 3) MCT-exposed group and treated with 500 mg/Kg/d
of NAC from day 14 to day 28 by daily gavage (n = 15).
MCT administration was performed with a single sub-
cutaneous injection (60 mg/kg) dissolved in 1 N HCl
and neutralized with 1 N NaOH. NAC and MCT were
purchased form Sigma-Aldrich (France, Lyon).
Hemodynamics
On day 28, right ventricular systolic pressure (RVSP),
mean pulmonary arterial pressure (mPAP) and cardiac
output (CO) were recorded. Rats were anesthetized with
35 mg/kg ketamine, 4 mg/kg xylasine and 0.5 mg/kg
acepromazine. A 3.5 French umbilical vessel catheter
(Tyco, Plaisir, France), angled to 90° over the distal 1 cm
and curved slightly at the tip, was introduced into the
right external jugular vein. With the angle directed
anteriorly, the catheter was inserted 2.5 cm proximally,
which placed the catheter in the right atrium. The
catheter was rotated 90° counterclockwise and inserted
1.0 cm further, which placed the catheter in the right
ventricle, and when advanced an additional 1.5 cm, in the
pulmonary artery. CO was measure by thermodilution: A
thermic probe was placed into left carotid artery and
0.25 mL of NaCl at 0°C was injected from the right exter-
nal jugular vein. Hemodynamic and CO values were auto-
matically calculated by the physiological data acquisition
Cardiomax III (Phymep, Paris, France). Total pulmonary
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Systemic pressure was measured with a 25G catheter in-
troduced in the left carotid artery.
Tissue preparation
After exsanguination via the abdominal aorta, lungs were
flushed with NaCl at 37°C in order to remove circulating
cells. For each animal, the left lung was distended by
infusion of OCT diluted in phosphate buffered saline
(PBS) (1:1) into the trachea to preserve lung morphology,
quick-frozen in isopentane on dry ice and stored at −80°C.
Each lobe from the right lung was dissected and snap
frozen in liquid nitrogen for molecular experiments.
Right ventricular hypertrophy was measured by Fulton’s
index. The right ventricle (RV) was dissected from the left
ventricle plus septum (LV + S), and these dissected sam-
ples were weighed to obtain the right ventricle-to-left
ventricle plus septum ratio [RV/(LV + S)].
Pulmonary vascular morphometry
Pulmonary vascular remodeling was measured by degree
of occlusion of capillary arteries on 7 μm-thick sections
of frozen lung tissue. Slices were fixed with acetone for
10 minutes at room temperature and then saturated with
human (10%) and donkey (10%) sera in PBS for 1 hour
at room temperature. We used mouse anti alpha Smooth
Muscle Actin (α-SMA)-FITC from Sigma-Aldrich (clone
1A4, dilution 1/100) and rabbit anti von Willebrand Factor
(Dako, dilution 1/100). Primary antibodies were incubated
overnight at 4°C. Antibody binding was detected with
secondary donkey anti-rabbit-Cy3 (1/100) from Jackson
ImmunoResearch. One lung section per rat was analyzed
(n = 14 rats per group) and all capillary arteries were
classified in 4 categories: not muscularized, partially
muscularized, fully muscularized and completely oc-
cluded according the presence or not of SMC-actin
staining around vWF + precapillary arteries (<50 μm).
Right ventricular histology
Seven μm-thick sections of frozen RV were stained by
hematoxylin-eosin or Sirius red for cardiomyocyte
circumference and percentage of collagen area analysis
respectively. Cardiomyocyte circumference was mea-
sured on transversely cut myocardial fibers and was
traced on the cellular border on photomicrograph of
60 cardiomyocytes (20 cardiomyocytes per field, 3 fields
per slice) from 3 to 4 rats per group with a computer-
assisted image-analysis system (NIS-Element BR 2.30).
Photomicrographs of transverse sections of the heart
stained with Sirius red were taken to measure collagen
content of the heart using ImageJ software®. The per-
centage of collagen area was calculated on 20 fields per
slice for each rat dividing the Sirius red-stained area by
the total RV tissue area.Gene quantification by quantitative real-time reverse
transcription polymerase chain reaction (RT-qPCR)
RNA was extracted from the right lungs of rats with
the total RNA isolation Mini kit (Agilent technologies,
France) and then eluted from silicate columns and
reverse-transcribed using Omniscript Reverse Tran-
scription kit (Qiagen, Courtaboeuf, France). Constitu-
tively expressed β actin was selected as an internal
housekeeping gene control in the comparative (2-ΔΔCt)
Ct method for the relative quantification of IL-6 mRNA
expression. IL-6 and β actin gene expressions were quanti-
fied by RT-PCR with TaqMan Gene Expression Assays β
actin [Rn00667869_m1], IL-6 [Rn01410330_m1], and Taq-
Man Universal PCR Master Mix followed in an ABI
Prism7000 Sequence Detection System (Applied Biosys-
tems, Courtaboeuf, France).
Assessment of inflammatory cells infiltration
Immunolabeling on lung 7 μm-thick sections was per-
formed against the rat monocyte/macrophage marker
ED-1 and dendritic cell marker OX62. The number of
ED-1–positive cells was determined in 5 fields for each
rat (n = 6 rats per group) and the number of OX62-
positive cells was determined in 6 to 10 pulmonary
artery adventitia for each rat (n = 3 rats per group).
Analysis
Quantitative variables were presented as mean values ± SD.
Comparisons for all parameters were analyzed by one-
way analysis of variance followed by Bonferroni’s post-
hoc test or a Kruskal-Wallis test followed by a Dunn’s
post-hoc test for small effectives (PRISM software,
GraphPad®, San Diego, LA). Statistical significance was
defined as p < 0.05.
Results
NAC improves cardiac function and decreases pulmonary
vascular remodeling in MCT-induced PH with no effect on
systemic pressure
Rats exposed to MCT consistently developed significant
PH at day 28, with an increase of RVSP and mPAP, a
fall of CO associated with high TPR. Right ventricular
hypertrophy assessed by the RV/(LV+S) ratio was in-
creased after MCT exposure due to pressure overload.
Treatment with NAC from day 14 to day 28 significantly
improved CO, TPR and RV hypertrophy, without effect on
RVSP and mPAP (Table 1).
The analysis of the pulmonary vacular remodeling
quantified by the degree of occlusion of pulmonary ca-
pillary vessels highlighted a significant increase in the
muscularization of small precapillary pulmonary arteries
after MCT exposure, associated with a decrease in per-
centage of low-resistance non-muscularized vessels. Treat-
ment with NAC significantly decreased muscularization of
Table 1 Hemodynamic data
Cont MCT MCT + NAC
RVSP (mmHg) 38.4 ± 6.0 102.6 ± 12.1* 93.1 ± 24.7*
mPAP (mmHg) 14.1 ± 1.6 34.6 ± 5.8* 36.6 ± 12.2*
CO (mL.min−1) 116.6 ± 14.6 45.1 ± 4.8* 80.4 ± 21.2*#
TPR (mmHg.min.mL−1) 0.12 ± 0.02 0.71 ± 0.14* 0.50 ± 0.17*#
RV/LV + S 0.28 ± 0.04 0.67 ± 0.08** 0.49 ± 0.07**##
NAC improves MCT-induced cardiac dysfunction without effect on right
ventricle and pulmonary artery pressure. Data are represented as mean ± SD.
RVSP: Right ventricular systolic pressure, mPAP: mean pulmonary arterial pressure,
CO: cadiac output, TPR: total pulmonary resistances. *p < 0.05 vs cont, **p < 0.001
vs cont, #p < 0.05 vs MCT, ##p < 0.001 vs MCT (n = 8–14).
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muscularized ones (Figure 1). On the other hand, systemic
pressure measured in each group showed no differences
(140.3 ± 10.6, 123.8 ± 18.3 and 126.7 ± 18.4 for control,
MCT and MCT+NAC groups respectively) as well as
heart rate (data not shown) excluding a peripheral benefi-
cial impact of NAC.
NAC attenuates inflammatory gene expression and
pulmonary infiltration of inflammatory cells
Development of PH in MCT-exposed rats was associated
with upregulation of pro-inflammatory IL-6 mRNA ex-
pression in total lung. Treatment with NAC induced a
significant decrease of IL-6 mRNA expression (0.36 ±
0.14, 2.40 ± 0.50, 1.18 ± 0.62 for control, MCT and MCT+
NAC groups respectively p < 0.05). In the lungs of MCT-Figure 1 NAC decreases MCT-induced pulmonary vascular remodelin
muscularized (C) and completely occluded (D) precapillary pulmonary arte
dot plot. *P < 0.05 vs cont, #p < 0.05 vs MCT) (n = 7–14 per group).treated rats, the number of ED-1–positive macrophages
was significantly increased compared to control group
(116 ± 8 vs. 30 ± 3, p < 0.05). NAC treatment halved lung
infiltration of ED-1–positive cells in MCT-exposed rats
(61 ± 8, p < 0.05) (Figure 2A). Similar results were ob-
tained for OX-62-positive dendritic cells in the pulmonary
arteriolar adventitia of rats with a significant increase in
the MCT group compared to control group (9.3 ± 1.05 vs.
2.5 ± 0.46, p < 0.05) and an improvement after NAC treat-
ment (5.5 ± 0.82, for MCT +NAC, p < 0.05 as compared
to MCT, Figure 2B). Thus, monocytes/macrophages and
dendritic cell accumulation into lung tissue is markedly
attenuated by NAC treatment.NAC attenuates histological signs of right ventricular
damage due to PH
The circumference of RV cardiomyocytes doubled in
MCT rats at 28 days compared to controls (625 ± 69
vs. 328 ± 46 μm2, p < 0.001). Treatment with NAC two
weeks after MCT exposure led to decreased cardio-
myocytes hypertrophy (439 ± 21 μm2, p < 0.001,
Figure 3A). Similar results have been obtained for
collagen content (fibrosis), with a significant elevation
in RV of MCT exposed rats (14.1 ± 0.8 vs. 6.0 ± 0.7% for
MCT and control group respectively, p < 0.001), and a re-
duction after treatment with NAC (14.1 ± 0.8 vs. 8.8 ±
0.1% for MCT and MCT+NAC groups respectively,
p < 0.001) (Figure 3B).g. Percentage of not muscularized (A), partially muscularized (B), fully
ries in control, MCT and MCT + NAC groups are represented in scatter
Figure 2 NAC reduces monocrotaline-induced pulmonary accumulation of ED-1 and OX-62 positive cells. Representative fluorescent
images compare the presence of (A) ED-1 positive monocytes/macrophages (red fluorescence arrows) in control rat (1) and lung of MCT-treated
rats (2). NAC treatment substantially reduced the number of ED-1 positive cells in the lungs of MCT-treated rats (3). Immunofluorescent labelling
for α-smooth muscle actin (green) was used to indentify vascular smooth muscle cells (blue fluorescence: nuclei). Presence of (B) dendritic cells
OX62 positive leucocytes (red fluorescence arrows) in lung of control rat (1) and MCT-treated rats (2). NAC treatment substantially reduced the
number of dendritic cells in the lungs of MCT-treated rats (3). 4: Bar graphs are summary data for mean number of ED-1+ cells/field and OX62+
cells/adventitia (mean ± SEM). *P < 0.05 vs cont, #p < 0.05 vs MCT) (n = 20–30 per group).
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In this study, we report that NAC reduces TPR and im-
proves right ventricular function in rats with MCT-
induced PH, partly through its immune-modulatory and
cardioprotective properties. Due to the strong rationale
of inflammation in PAH pathophysiology, a lot of studies
have already evaluated the benefit of immune-modulatory
drugs in PH animal models. However, most of them ex-
plored the drug before installation of pulmonary vascular
lesions reflecting their capacity to prevent the disease andnot to cure it. Despite improvement in the field of PAH,
diagnosis of PAH patients is still delayed with an advanced
progression of the disease, while breathlessness appears
when 80% of small pulmonary arteries are affected. It is
therefore essential that drugs predicted for PH improve-
ment be studied in advanced conditions of the disease. In
this study, NAC was introduced 2 weeks after MCT ex-
posure when pulmonary vascular lesions were already de-
veloped [29], as it has been previously performed in a
study using dexamethasone in the same model [30]. We
Figure 3 NAC decreases cardiomyocytes hypertrophy and fibrosis in RV rats with PH. In the first part (A), representative image of
cardiomyocytes in RV of control rat (1) MCT rats (2) and MCT rats treated with NAC from days 14 to day 28 after MCT exposure (3). In the second
part (B), representative image of collagen (red stained) content in RV of control rat (1) MCT rats (2) and MCT rats treated with NAC from days 14
to day 28 after MCT exposure (3). All photomicrographs were taken at G20 magnification. 4: Bar graphs are summary data for cardiomyocyte area
(n = 180 per group) and collagen area fraction (n = 60 per group), as mean ± SEM and *P < 0.05 vs cont (n = 180 per group).
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plicity and reproducibility. Although criticized by some
authors, MCT remains a great model regarding inflamma-
tion process in PH [31]. It is noteworthy that other models
of PH have been developed: Sugen + hypoxia- and MCT +
pneumonectomy-induced PH. These models display in-
timal remodeling and some degree of angioproliferative le-
sions resembling plexiform lesions. Even if these lesions
are pathognomonic of PAH (group 1 of the updated clin-
ical classification of PH [32]), it is not in fact known
whether these lesions participate to the elevated pulmon-
ary vascular resistance responsible for PAH, or if they are
just a surrogate marker of disturbed blood flow within thePAH-affected pulmonary vasculature. In contrast, the pro-
gressive neomuscularization and obstruction of precapil-
lary resistance arteries occuring in the MCT-induced PH
is a robust mechanism of TPR elevation. However it re-
mains interesting to test NAC efficacy in other models of
PAH representative of different etiologies and of po-
tential different pathomechanisms, like chronic hyp-
oxia or hypoxia + sugen-induced PH.
In our current study, two weeks treatment with NAC
14 days after MCT exposition led to a significant decrease
of pulmonary vascular remodeling characterized hemo-
dynamically by a reduced level of TPR and an unmodified
mPAP and RVSP. In a previous study, we reported that
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high-flow challenged animal model associated with MCT
correlated with lung expression of pro-inflammatory cyto-
kines and recruitment of both monocyte/macrophages and
dendritic cells in the pulmonary vasculature [17]. The
reduction of the lung inflammatory status observed in this
study with the reduced lung cytokine expression and in-
flammatory cells recruitment could partly explain these re-
sults. Potential disease-relevant mechanistic factors of NAC
include NF-κB and Angiotensin II (Ang II) signaling.
Firstly, NF-κB is the key inflammatory transcription factor
well known to be activated by oxidative stress [33] which is
implicated in human [21] and experimental PAH [17]; its
activation leads to the upregulation of chemokines and in-
flammatory cytokines implicated in human IPAH [34] and
in the MCT-induced PH model where its inhibition amelio-
rates PH - both preventatively and therapeutically [35,36].
Secondly, involvement of Ang II through its receptor 1
(AT(1)) activation was reported in the pathophysiology of
PAH [37]. Interestingly, NAC decreases Ang II binding
to the AT(1) receptor in vascular smooth muscle cells
(VSMC) in a concentration-dependent manner, leading
to a reduction of VSMC proliferation [38]. The benefi-
cial effect of NAC could therefore be in part depends on
this property. Although it has been reported evidence of
NAC-induced vasodilation and hypotension [39,40], we
didn’t found any systemic effect of NAC in our study.
PAH is characterized by remodeling of the pulmonary
arterial vessels, which involves progressive distal vessel
obliteration leading to an increase in the TPR. This
increase in TPR leads to an increase in the RV afterload
leading to RV dysfunction and CO decrease. In our
study, mPAP was not statistically changed but TPR
were decreased, the degree of distal obliteration (%) was
reduced, and CO was increased in the NAC treated group.
We might explain the decrease in TPR by the significant
decrease in the distal artery occlusion. The simplified
classical relationship between mPAP, CO and TRP is the
following: mPAP =CO*TPR. In other terms, CO =mPAP/
TPR. So even if mPAP remains not statistically changed,
the increase in CO might be the consequence of reduced
TPR and therefore of reduced distal pulmonary vascular
occlusion. CO depending on proper calibration of RV
contractility and impedance to blood flow through the
lungs, NAC may also have a direct beneficial impact on
CO though improvement of RV contractility. However,
this parameter has not been analyzed in our study but
deserve further investigation in order to ascertain a
direct RV protective effect in PH. Another argument in
favor of a direct impact of NAC on right ventricle is
provided in a recent review by Voelkel on oxidative
stress and PH [41]. In this review, influence of oxidative
stress on pulmonary vasculature and cardiac cells was
extensively analyzed, particularly in the RV failuremechanism. The authors propose a kinetic model of
oxidative stress with an impact on pulmonary vascula-
ture at an early stage and on RV at a later stage and
throughout the development of the RV disease. In order
to confirm their hypothesis on cardiac dysfunction,
protandim treatment (having antioxidant properties) of
the Su/Hx rats prevented the development of RV failure
and fibrosis. Analysis of mitochondrial and metabolic
gene remodeling in the RV as it was recently reported
by Gomez et al., would probably also afford significant
information on cardio protective pathway of NAC and
need to be performed in next experiments [42].
Pressure overload usually increases pulmonary vascular
resistance and cardiomyocyte stress leading to cardiomyo-
cyte hypertrophy and extracellular matrix changes with
fibrosis. Endomyocardial biopsy specimens from pa-
tients with PAH show increased levels of fibrosis affect-
ing myocardial systolic and diastolic function [43,44]. In
a recent review analyzing the RV under pressure, mala-
daptative neurohormonal signaling, oxidative stress and
inflammation in the heart were reported as processes
possibly accelerating the development of right-heart
failure in PAH [16]. In vitro and in vivo studies have
shown that reactive oxygen species (ROS) induce car-
diomyocyte hypertrophy as well as fibrosis [45] and in
the MCT-induced model of PH, right ventricular failure
was associated with oxidative stress [46]. Moreover,
in conditions of ischemia/reperfusion, macrophages
recruit neutrophils through the secretion of IL-6, which
are an important source of ROS [16]. Interestingly, Ang
II induces cardiomyocyte hypertrophy, inflammation,
fibrosis and contractile dysfunction through in part by
the formation of ROS [47]. Due to its antioxidant, anti-
inflammatory and cardioprotective properties, NAC
improved right ventricular function (CO) with inhib-
ition of cardiomyocyte hypertrophy and fibrosis.
Although specific mechanisms of NAC on RV preser-
vation still remain elusive, improvement of right ven-
tricular function with NAC is a particularly relevant
issue since despite PAH specific therapeutics, pulmonary
microvascular obstruction usually progresses and im-
poses an increasing load on the RV [48]. The patient
outcome is therefore predominantly determined by the
response of the RV to the increased afterload and RV
function is therefore a strong marker of prognosis and
disease severity [49]. Advance in new therapies acting on
right ventricular function is therefore relevant in PAH
management. However, current available or experimen-
tal PAH treatments are used to induce pulmonary vaso-
dilation and reverse pulmonary vascular remodeling, and
little is known about their effect on the heart. An ideal
PAH treatment strategy would therefore both reduce
pulmonary vascular resistance and improve right ventricu-
lar function. Here, we report that NAC, a well-known safe
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parameters in an experimental model of PH.
Conclusions
In conclusion, NAC could be a potential additive treat-
ment in PAH management preserving hemodynamic and
right heart function. Further experimental and preclinical
studies are needed to confirm these benefit effect.
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